Calidi Biotherapeutics, Inc.
CLDI
Rank in Stocks
#32212
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused... Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Share Price
$0.7331
Last synced: 2026-11-09
Market Cap
$1.89M
Change (1 day)
4.71%
Change (1 year)
-49.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Calidi Biotherapeutics, Inc. (CLDI)
Category
Healthcare
Operating Margin for Calidi Biotherapeutics, Inc. (CLDI)
Operating Margin as of November 2026 TTM: 0.00%
According to Calidi Biotherapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Calidi Biotherapeutics, Inc. from 2020 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -51,395.56% | 2,101.55% |
| 2021 | -2,334.52% | 0.00% |
| 2020 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Calidi Biotherapeutics, Inc.'s operating margin
What was Calidi Biotherapeutics, Inc.'s operating margin in 2025?
In 2025, Calidi Biotherapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Calidi Biotherapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Calidi Biotherapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-51,395.56%).
How does Calidi Biotherapeutics, Inc.'s operating margin compare with similar companies?
Calidi Biotherapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.